Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 38
Filter
1.
Transplant Proc ; 50(10): 3521-3526, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30577230

ABSTRACT

BACKGROUND: In new organ allocation policy, patients with hepatocellular carcinoma (HCC) experience a 6-month delay in being granted Model for End-Stage Liver Disease exception points. However, it may not be fair for patients at risk of early progression of HCC. METHODS: All patients who were diagnosed as United Network for Organ Sharing (UNOS) stage 1 or 2 of HCC between January 2004 and December 2012 were included. Patients who received surgical resection or liver transplant (LT) as a primary treatment and who did not receive any treatment for HCC were excluded. Patients with baseline Model for End-Stage Liver Disease score ≥22 were also excluded because they have a higher chance of receiving LT. Patients who developed extrahepatic progression within 1 year were considered as high-risk for early recurrence after LT. RESULTS: A total of 586 patients were included. Mean (SD) age was 59.9 (10.3) years and 409 patients (69.8%) were men. The cumulative incidence of estimated dropout was 8.9% at 6 months; size of the maximum nodule (≥3 cm) and nonachievement of complete response were independent factors. Extrahepatic progression developed in 16 patients (2.7%) within 1 year; size of the maximum nodule (4 cm) and alpha-fetoprotein level (>100 ng/mL) were independent predictors. CONCLUSIONS: The estimated dropout rate from the waiting list within 6 months was 8.9%. Advantage points might be needed for patients with maximum nodule size ≥3 cm or those with noncomplete response. However, in patients with maximum nodule size ≥4 cm or alpha-fetoprotein level >100 ng/mL, caution is needed.


Subject(s)
Carcinoma, Hepatocellular , Liver Neoplasms , Liver Transplantation , Patient Selection , Waiting Lists , Adult , Aged , Carcinoma, Hepatocellular/pathology , Carcinoma, Hepatocellular/surgery , Disease Progression , Female , Humans , Liver Neoplasms/pathology , Liver Neoplasms/surgery , Male , Middle Aged , Risk Factors , Waiting Lists/mortality
2.
J Viral Hepat ; 25(11): 1321-1330, 2018 11.
Article in English | MEDLINE | ID: mdl-29772084

ABSTRACT

Entecavir 0.5 mg (ETV) is widely used among treatment-naïve chronic hepatitis B (CHB) patients. However, 10%-30% of patients show partial virologic response (PVR) to the drug. If the hepatitis B virus (HBV) continues to replicate, the underlying liver disease may progress. Herein, we compared the efficacy of switching to tenofovir disoproxil fumarate (TDF) with that of continuing ETV in CHB patients with PVR to ETV. This was an open-label randomized controlled trial including CHB patients who had been receiving 0.5 mg of ETV for >12 months, but who still had detectable HBV DNA levels of >60 IU/mL without known resistance to ETV. Sixty patients were enrolled and 45 qualified for the study: Twenty-two patients were randomly assigned into the TDF group and 23 into the ETV group. After 12 months of treatment, the virologic response rate (HBV DNA <20 IU/mL) was significantly higher in the TDF group than in the ETV group, as measured using per-protocol analysis (55% vs 20%; P = .022) and intention-to-treat analysis (50% vs 17.4%; P = .020). The reduction in HBV DNA was greater (-1.13 vs -0.67 log10 IU/mL; P = .024), and the mean HBV DNA level was lower (1.54 vs 2.01 log10 IU/mL; P = .011) in the TDF group than in the ETV group. In conclusion, to achieve optimal response in CHB patients with PVR to ETV, switching to TDF would be a better strategy than continuing ETV. Appropriate modification of therapy would further improve the outcome of chronic HBV infection.


Subject(s)
Drug Substitution , Guanine/analogs & derivatives , Hepatitis B virus/drug effects , Hepatitis B, Chronic/drug therapy , Tenofovir/pharmacology , Tenofovir/therapeutic use , Adult , Antiviral Agents/pharmacology , Antiviral Agents/therapeutic use , DNA, Viral/blood , Female , Guanine/pharmacology , Guanine/therapeutic use , Hepatitis B Antibodies/blood , Hepatitis B Antigens/blood , Hepatitis B virus/immunology , Humans , Male , Middle Aged , Odds Ratio , Treatment Outcome , Viral Load/drug effects
3.
Transplant Proc ; 43(6): 2421-3, 2011.
Article in English | MEDLINE | ID: mdl-21839282

ABSTRACT

Outflow obstruction or stenosis of a hepatic graft is a rare but serious complication after liver transplantation, with a reported incidence of 1% to 6%. It can cause signs of portal hypertension, renal dysfunction, or lower-extremity edema depending on the level of obstruction, which may lead to patient mortality. Most reported cases show a stenosis at either the inferior vena cava (IVC) or one of the hepatic veins. Herein we have reported our experience of concurrent suprahepatic IVC and hepatic vein stenoses after orthotopic liver transplantation with related imaging findings and a successful treatment outcome. Due to the complexity of stenoses, two self-expandable metallic stents were placed simultaneously using different venous accesses.


Subject(s)
Budd-Chiari Syndrome/etiology , Liver Cirrhosis, Alcoholic/surgery , Liver Transplantation/adverse effects , Vena Cava, Inferior , Venous Thrombosis/etiology , Budd-Chiari Syndrome/diagnostic imaging , Budd-Chiari Syndrome/therapy , Humans , Male , Middle Aged , Phlebography/methods , Stents , Tomography, X-Ray Computed , Treatment Outcome , Vena Cava, Inferior/diagnostic imaging , Venous Thrombosis/diagnostic imaging , Venous Thrombosis/therapy
6.
J Viral Hepat ; 18(9): 631-6, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21029256

ABSTRACT

The findings of several studies suggest that liver stiffness values can be affected by the degree of intrahepatic congestion respiration influence intrahepatic blood volume and may affect liver stiffness. We evaluated the influence of respiration on liver stiffness. Transient elastography (TE) was performed at the end of inspiration and at the end of expiration in patients with chronic liver disease. The median values obtained during the inspiration set and during the expiration set were defined as inspiratory and expiratory liver stiffness, respectively. A total of 123 patients with chronic liver disease were enrolled (mean age 49years; 64.2% men). Liver cirrhosis coexisted in 29 patients (23.6%). Expiratory liver stiffness was significantly higher than inspiratory liver stiffness (8.7 vs 7.9kPa, P=0.001), while the expiratory interquartile range/median ratio (IQR ratio) did not differ from the inspiratory IQR ratio. Expiratory liver stiffness was significantly higher than inspiratory liver stiffness in 49 (39.8%) patients (HE group), expiratory liver stiffness was significantly lower than inspiratory stiffness in 15 (12.2%) patients, and there was no difference in 59 (48.0%) patients. Liver cirrhosis was more frequent in those who had a lower liver stiffness reading in expiration, and only the absence of liver cirrhosis was significantly associated with a higher reading in expiration in multivariate analysis. In conclusion, liver stiffness was significantly elevated during expiration especially in patients without liver cirrhosis. The effect of respiration should be kept in mind during TE readings.


Subject(s)
Elasticity Imaging Techniques/methods , Exhalation , Inhalation , Liver Cirrhosis/diagnostic imaging , Liver/diagnostic imaging , Adolescent , Adult , Aged , Biopsy , Chronic Disease , Cohort Studies , Elasticity , Female , Hepatitis, Chronic/pathology , Hepatitis, Chronic/virology , Humans , Liver/pathology , Liver Cirrhosis/pathology , Male , Middle Aged , ROC Curve , Regression Analysis , Young Adult
7.
J Viral Hepat ; 18(4): 287-93, 2011 Apr.
Article in English | MEDLINE | ID: mdl-20367793

ABSTRACT

Clevudine shows high rates of virologic and biochemical responses in patients with chronic hepatitis B. However, the efficacy and safety of clevudine in patients with cirrhosis are unknown. The aims of this study were to evaluate the safety and to assess the virologic and the biochemical responses to clevudine in patients with cirrhosis with chronic hepatitis B virus (HBV) infection. We reviewed data from treatment-naïve patients with chronic hepatitis B with and without cirrhosis who started clevudine between April 2007 and March 2008 (n = 52, hepatitis B without cirrhosis n = 21 and chronic hepatitis B with cirrhosis n = 31) at Korea University Ansan/Guro Hospital. All of the patients were treated for more than 48 weeks. The mean age was older in the patients with cirrhosis. Baseline HBV DNA levels were 6.9 and 7.78 log copies/mL (P = 0.042), and alanine aminotransferase (ALT) levels were 104.9 and 147.4 IU/L (P = 0.204), for those with and without cirrhosis, respectively. Virologic response (HBV DNA <1000 copies/mL) (87.1%vs 71.4%, P = 0.24) and biochemical response (83.9%vs 80.9%, P = 0.99) at week 48 were not significantly different between the two groups. Early virologic response at week 12 was even higher in the patients with cirrhosis (61.3%vs 28.6%, P = 0.026). Neither ALT flare nor newly onset hepatic decompensation was found in the patients with cirrhosis, whereas ALT flare was transiently observed in 14.3% of the chronic hepatitis group. In conclusion, although clevudine may produce a transient elevation of ALT during the early treatment period, such findings were not observed in patients with cirrhosis and the virologic and biochemical responses of the groups were comparable.


Subject(s)
Antiviral Agents/administration & dosage , Arabinofuranosyluracil/analogs & derivatives , Hepatitis B, Chronic/drug therapy , Liver Cirrhosis/drug therapy , Adult , Alanine Transaminase/blood , Antiviral Agents/adverse effects , Arabinofuranosyluracil/administration & dosage , Arabinofuranosyluracil/adverse effects , DNA, Viral/blood , Female , Hepatitis B, Chronic/complications , Humans , Korea , Liver Function Tests , Male , Middle Aged , Treatment Outcome , Viral Load
8.
Clin Pharmacol Ther ; 88(3): 360-8, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20664537

ABSTRACT

Oltipraz is a potential candidate drug for the treatment of liver fibrosis (LF) and liver cirrhosis (LC). The pharmacokinetics of oltipraz and its major rearranged metabolite (7-methyl-6,8-bis(methylthio)H-pyrrolo[1,2-a]pyrazine (RM)) were evaluated after single-dose (30-90 mg) and multiple-dose (60 mg b.i.d. or 90 mg q.d. for 24 weeks) oral administration of oltipraz to patients with LF or LC. Oltipraz was safe and well tolerated in both studies. In the single-dose study, the area under the plasma concentration-time curve (AUC), peak plasma concentration (C(max)), and terminal half-life (t(1/2)) of oltipraz as well as the AUC of its RM were dose dependent. Oltipraz was rapidly absorbed; the time to reach C(max) (T(max)) was 2-4 h. The conversion of oltipraz to RM was also rapid and substantial (AUC of RM from time 0 to the last measured concentration (AUC(last, RM))/AUC(last, oltipraz), 42-61%). In the multiple-dose study, the level of transforming growth factor-beta1 (TGF-beta1) (a blood fibrosis marker) was suppressed at steady-state plasma concentrations of approximately 20-60 ng/ml of oltipraz or of approximately 60-140 ng/ml of oltipraz plus RM. Overall, the pharmacokinetics, safety, and efficacy of oltipraz suggest that it may be helpful in the treatment of patients with LF or LC, at an optimal dosing regimen.


Subject(s)
Antiviral Agents/pharmacokinetics , Liver Cirrhosis/drug therapy , Pyrazines/pharmacokinetics , Transforming Growth Factor beta1/metabolism , Administration, Oral , Adult , Antiviral Agents/administration & dosage , Antiviral Agents/pharmacology , Area Under Curve , Dose-Response Relationship, Drug , Double-Blind Method , Drug Administration Schedule , Female , Half-Life , Humans , Liver Cirrhosis/pathology , Male , Middle Aged , Pyrazines/administration & dosage , Pyrazines/pharmacology , Thiones , Thiophenes
12.
Aliment Pharmacol Ther ; 32(3): 498-505, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20491742

ABSTRACT

BACKGROUND: Interquartile range/median value (IQR/M) of liver stiffness measurement (LSM) is a factor in chronic hepatitis C (CHC) leading to over estimation of fibrosis by Fibroscan. AIM: To investigate factors that affect the accuracy of LSM in chronic hepatitis B (CHB). METHODS: One hundred and ninety-nine patients were enrolled. Only procedures yielding > or =10 valid measurements were considered reliable. Liver fibrosis was evaluated using the Batts and Ludwig system. Liver biopsy (LB) specimens <15 mm were considered ineligible. RESULTS: The mean age (142 men and 57 women) was 40.1 years. A significant discordance (discordance of at least two stages between LB and LSM) was identified in 38 (19.1%) and 47 (23.6%) patients respectively, according to Marcellin et al. and Chan et al.'s cutoff values. In multivariate analyses, BMI and fibrosis stage (F0-2 vs. F3-4) were identified as independent predictors for significant discordance (P = 0.040; hazard ratio [HR], 1.126; 95% confidence interval [CI], 1.005-1.261 and P = 0.036; HR, 0.450; 95% CI, 0.213-0.949 respectively) with Marcellin et al.'s cutoffs, whereas fibrosis stage was the only independent predictor (P = 0.004; HR, 0.300; 95% CI, 0.131-0.685) with Chan's cutoffs. CONCLUSIONS: Success rate and IQR/M were not predictive factors of the accuracy for diagnosing liver fibrosis by Fibroscan in CHB. Fibrosis stage (F0-2) was the only factor to predict significant discordance between LB and LSM.


Subject(s)
Hepatitis B, Chronic/diagnostic imaging , Hepatitis C, Chronic/diagnostic imaging , Liver Cirrhosis/diagnostic imaging , Adult , Biopsy , Elasticity Imaging Techniques , Female , Humans , Liver Cirrhosis/diagnosis , Male , Middle Aged , Sensitivity and Specificity
19.
Dig Liver Dis ; 41(2): 134-40, 2009 Feb.
Article in English | MEDLINE | ID: mdl-18436489

ABSTRACT

BACKGROUND/AIMS: Peptic ulcers occur more commonly in patients with liver cirrhosis (LC). Helicobacter pylori is recognized as the most important etiology in the pathogenesis of peptic ulcers. We investigated the efficacy of proton pump inhibitor (PPI)-based triple therapy in patients with chronic liver disease and peptic ulcer. PATIENTS AND METHODS: One hundred sixty-three patients with LC or chronic hepatitis (CH) with a peptic ulcer and proven H. pylori infection were included. The combination of PPI, amoxicillin (1.0 g), and clarithromycin (500 mg), each given twice daily, was administered for 1 or 2 weeks. The eradication of H. pylori was determined by the rapid urease test, histology, or the 13C-urea breath test at least 4 weeks after completing the treatment. RESULTS: The eradication rate of H. pylori was similar between the LC and CH groups; 82.6% and 88.1%, respectively. In addition, there were no significant differences in eradication rates between the patients with Child-Pugh class A and Child-Pugh class B/C disease. The side effects in each group were generally mild. Only the serum ALT levels showed a significant correlation with the success of H. pylori eradication in both the LC and CH groups. CONCLUSION: The PPI-based triple therapy achieves high eradication rates for H. pylori infection, in patients with chronic liver disease, without significant side effects.


Subject(s)
Helicobacter Infections/drug therapy , Helicobacter Infections/microbiology , Helicobacter pylori/isolation & purification , Hepatitis, Chronic/microbiology , Liver Cirrhosis/microbiology , Peptic Ulcer/drug therapy , Peptic Ulcer/microbiology , Adult , Alanine Transaminase/blood , Amoxicillin/therapeutic use , Anti-Bacterial Agents/therapeutic use , Breath Tests , Clarithromycin/therapeutic use , Drug Administration Schedule , Drug Therapy, Combination , Endoscopy, Digestive System , Female , Helicobacter Infections/diagnosis , Humans , Male , Middle Aged , Peptic Ulcer/diagnosis , Proton Pump Inhibitors/therapeutic use , Retrospective Studies , Severity of Illness Index , Treatment Outcome
20.
Methods Inf Med ; 45(1): 37-43, 2006.
Article in English | MEDLINE | ID: mdl-16482368

ABSTRACT

OBJECTIVES: Scoring and staging systems are used to determine the order and class of data according to predictors. Systems used for medical data, such as the Child-Turcotte-Pugh scoring and staging systems for ordering and classifying patients with liver disease, are often derived strictly from physicians' experience and intuition. We construct objective and data-based scoring/staging systems using statistical methods. METHODS: We consider Cox linear regression modeling and recursive partitioning techniques for censored survival data. In particular, to obtain a target number of stages we propose cross-validation and amalgamation algorithms. We also propose an algorithm for constructing scoring and staging systems by integrating local Cox linear regression models into recursive partitioning, so that we can retain the merits of both methods such as superior predictive accuracy, ease of use, and detection of interactions between predictors. The staging system construction algorithms are compared by cross-validation evaluation of real data. RESULTS: The data-based cross-validation comparison shows that Cox linear regression modeling is somewhat better than recursive partitioning when there are only continuous predictors, while recursive partitioning is better when there are significant categorical predictors. The proposed local Cox linear recursive partitioning has better predictive accuracy than Cox linear modeling and simple recursive partitioning. CONCLUSIONS: This study indicates that integrating local linear modeling into recursive partitioning can significantly improve prediction accuracy in constructing scoring and staging systems.


Subject(s)
Medical Informatics/statistics & numerical data , Survival Analysis , Humans , Liver Diseases/classification , Proportional Hazards Models , Reproducibility of Results
SELECTION OF CITATIONS
SEARCH DETAIL
...